CD+3CD+28T细胞预测晚期消化道癌化疗疗效的初步研究  

Preliminary study on the prediction of chemotherapeutic efficacy in patients with advanced digestive cancer with CD+3CD28+T cell value

作　　者：韩琳[1] 裴毅[2] 

机构地区：[1]山西煤炭中心医院肿瘤科,太原030006 [2]山西省肿瘤医院老年病科

出　　处：《肿瘤研究与临床》2008年第7期460-461,464,共3页Cancer Research and Clinic

基　　金：山西省科技攻关项目(2006031090-01)

摘　　要：目的 探讨CD+3CD28+T细胞预测化疗疗效的价值.方法 经病理证实的晚期消化道癌患者38例,均有可测量的病变,采用流式细胞术检测化疗前外周血中CD+3CD28+T细胞的绝对数值,并选择10例健康体检者作为对照.所有患者均行化疗:胃癌DCF方案1个周期,肠癌FOLFOX方案2个周期,食管癌采用丝裂霉素+替加氟+顺铂2个周期,胆囊癌和胰腺癌均采用吉西他滨+替加氟+顺铂1个周期.按照WHO制定的疗效标准评价疗效,分为有效(完全缓解+部分缓解,CR+PR)组、稳定(SD)组和进展(PD)组,对各疗效组的CD+3CD28+T细胞水平进行统计分析.结果 CR+PR组的CD+3CD28+T细胞为(1055.0±545.8)个/μl,与对照组(1156.0±318.0)个/μl差异无统计学意义(P=0.549),SD组和PD组的CD+3CD28+T细胞分别为(748.6±266.7)个/μl、(525.6±243.5)个/μl,均低于对照组(P=0.002,P=0.000),CR+PR组高于PD组(P=0.001),SD组高于PD组(P=0.044).结论 CD+3CD+28T细胞水平低于对照组的晚期消化道癌患者化疗效果差.CD+3CD+28T细胞对预测化疗疗效可能有重要价值.Objective To investigate the relationship between CD+3CD28+T cell value and chemotherapeutic efficacy in patients with advanced digestive cancer. Methods 38 digestive cancer patients with distant metastatic lesion were included.10 healthy persons were as control group. The absolute counts of CD+3CD28+T cell were measured with flow eytometry in these patients before chemotherapy. All patients received chemotherapy, gastric cancer: DCF regimen (docetaxel plus tegafur and cisplatin, one cycle), colorectal cancer:. Folfox regimen (L-OHP plus tegafur, two cycles), esophageal cancer: mitomycin plus tegafur and cisplatin (two cycles), gallbladder or pancreatic cancer: gemzar plus tegafur and cisplatin (one cycle). According to WHO standard, the chemotherapeutic efficacy was determined, 38 patients were divided into three groups: CR+PR (complete remission plus partial remission), SD (stable of disease) and PD (progress of disease) group. Statistical analysis was used upon all data. Results There was no significant difference in value of CD+3CD28+ T cell between CR+PR group and control group (P=0.549). The value of CD+3CD28+ T cell in SD group and PD group were significantly decreased (P=0.002, P=0.000). The value of CD+3CD28+T cell in CR+PR group was more than that in PD group (P =0.001), while in SD group was more than in PD group (P = 0.044). Conclusion The efficacy is poor, if the value of CD+3CD28+ T cell in patients with advanced digestive cancer is less than that of in healthy persons in peripheral blood. Therefore, the value of CD+3CD28+ T cell is important for the early prediction of the efficacy before chemotherapy.

关 键 词：消化系统肿瘤 T淋巴细胞 药物疗法 治疗结果 

分 类 号：R735[医药卫生—肿瘤]